Submit RFP
+44 20 3821 1562
''
0
Years of Imaging Expertise!
0
Clinical Trials Supported
Global
Site & Investigator Network
Compliance & Certificates
SOC 2 TYPE II
HHS-Seal
GDPR
FDA 21 CFR Part 11
ISO 13485
Imaging endpoints and cardiac safety

Cardiovascular Imaging Endpoints and Imaging-Based Cardiac Safety

Reliable cardiovascular imaging data depend on standardized acquisition, robust quality control and consistent expert interpretation.

 

Cardiovascular imaging provides measures of cardiac structure, function, myocardial tissue characteristics and vascular anatomy to assess disease and treatment response. These assessments support cardiovascular clinical trials and the evaluation of cardiovascular effects in oncology, metabolic, autoimmune and rare disease studies.

 

IAG provides end-to-end imaging support, from imaging strategy and protocol development through site feasibility, acquisition standardization, centralized image quality control, quantitative analysis, blinded expert review and data delivery. Predefined acquisition and analysis methods support consistent assessment across sites and timepoints.

 

Through a longstanding partnership, sponsors can also access specialist cardiac safety services, coordinated with IAG’s imaging support, with study workflows managed in DYNAMIKA™.

Learn more
What our cardiovascular imaging team does

Cardiovascular Imaging Capabilities

Imaging strategy, site feasibility, acquisition standardization, centralized image quality control, quantitative analysis and blinded expert review across echocardiography (ECHO/cardiac ultrasound), cardiac CT, CT angiography, cardiac MRI, vascular ultrasound/Doppler and MR angiography.

 

Cardiac and vascular imaging assessments

 

Assessment of cardiac structure and function, myocardial tissue characteristics, vascular anatomy and blood flow, using study-specific acquisition and analysis methods. These assessments support cardiovascular endpoints and the evaluation of treatment effects across cardiovascular, oncology, metabolic, autoimmune and rare disease clinical trials.

 

Coordinated specialist cardiac safety services

 

Through a longstanding partnership, sponsors can also access specialist cardiac safety services, including ECG and QT/QTc analysis, ambulatory ECG and rhythm monitoring, and remote monitoring. These services are coordinated with IAG’s imaging support, with study workflows managed in DYNAMIKA™.

 

 

What our cardiovascular imaging team does

Cardiovascular Imaging Capabilities

Imaging strategy, site feasibility, centralized image quality control and blinded central review across echocardiography and cardiac CT — complementing ECG and rhythm-monitoring services.

Imaging-based cardiovascular safety
Assessment of cardiac structure, function and vascular findings integrated into oncology, metabolic, autoimmune and rare disease clinical trials, where relevant to the investigational therapy and study objectives.
Integrated with broader cardiac safety assessments
Our scope focuses on imaging-based endpoints and can complement ECG, rhythm-monitoring and other specialist cardiac safety services within an integrated study strategy.
Study Phases

How IAG Supports Cardiovascular Trials

Cardiovascular efficacy endpoints and imaging-based cardiac safety, scaled to your phase.

01 ANY PHASE
Study Design & Site Readiness

Imaging endpoint selection, acquisition protocol development, site feasibility and imaging charter design, aligned with your study objectives.

Study Design & Site Readiness
02 PHASE I / II
Early Phase Trials

Acquisition standardization, site training, centralized quality control and quantitative analysis to assess baseline measures and treatment-related changes in cardiac and vascular structure and function.

Early Phase Trials
03 PHASE III
Late Phase Trials

Blinded expert review and quantitative analysis across global sites, supported by predefined assessment methods, reader qualification and consistent evaluation across study timepoints.

Late Phase Trials
04 RWE / AI
RWE & AI Studies

Imaging data curation, quality control, expert annotation and quantitative analysis to support real-world evidence studies and AI development.

RWE & AI Studies
The experts behind your reads

Our Cardiovascular Imaging Experts

Cardiac imaging specialists overseeing acquisition harmonization, image quality control and blinded central interpretation for efficacy and cardiac safety endpoints.

Prof. Emilio Vanoli MD
Prof. Emilio Vanoli MD
Scientific Advisor — Cardiology and Cardiovascular Diseases
Cardiology View Profile
Measures and modalities we work in

Cardiovascular Imaging Measures and Modalities

IAG provides quantitative analysis and blinded expert review of cardiac structure and function, myocardial tissue characteristics, vascular anatomy and blood flow. Harmonized acquisition and centralized quality control support consistent assessment across sites and study timepoints.

Criterion
Applies to
Echocardiography (ECHO / Cardiac Ultrasound)
• Ejection fraction, ventricular volumes and chamber dimensions • Systolic and diastolic function • Myocardial strain, including global longitudinal strain • Valvular function, including stenosis and regurgitation • Doppler velocities and derived pressure gradients
Cardiac CT
• Cardiac anatomy and chamber dimensions • Myocardial wall thickness • Valve anatomy and calcification • Aortic root and annular dimensions • Coronary artery calcium scoring using non-contrast acquisitions
CT Angiography (CTA)
• Coronary and peripheral vascular anatomy • Vessel diameter, lumen area and lesion length • Stenosis severity, occlusion and vessel patency • Coronary plaque burden and characteristics • Aneurysm dimensions
Cardiac MRI (CMR)
Ventricular volumes, ejection fraction and myocardial mass Global and regional ventricular function Myocardial tissue characterization, including scar, fibrosis and oedema Blood flow, regurgitant volumes and fractions using dedicated flow sequences
Vascular Ultrasound (Duplex / Doppler)
• Vessel dimensions and patency • Peak systolic and end-diastolic velocities • Flow direction and waveform analysis • Velocity ratios and stenosis assessment • Plaque assessment in applicable vascular territories
MR Angiography (MRA)
Vascular anatomy and vessel dimensions. Vessel patency, stenosis and occlusion. Aortic and other arterial aneurysm dimensions. Vascular abnormalities, including dissection and malformations
Indications we cover

Cardiovascular Indications We Support

IAG supports imaging endpoints in clinical trials of heart failure and cardiomyopathies, coronary artery disease and ischemic heart disease, structural heart and valvular disease, atrial fibrillation and other arrhythmias, and vascular disease.

Heart Failure and Cardiomyopathies
Assessment of ventricular volumes, ejection fraction, chamber dimensions, myocardial strain and myocardial tissue characteristics.
Category
Coronary Artery Disease and Ischemic Heart Disease
Assessment of coronary anatomy, calcium and plaque burden, stenosis severity, ventricular function and myocardial scar.
Category
Structural Heart and Valvular Disease
Assessment of valve anatomy and function, stenosis and regurgitation, chamber dimensions, and aortic root and annular measurements.
Category
Atrial Fibrillation and Rhythm-Intervention Studies
Assessment of atrial and pulmonary vein anatomy and cardiac structure and function to support ablation and other rhythm-intervention studies.
Category
Vascular Disease
Assessment of vessel dimensions, patency, stenosis and aneurysms, alongside Doppler measurements of blood-flow velocity and direction.
What the Platform Gives You

Why Sponsors Choose IAG

DYNAMIKA™ centralizes cardiovascular imaging data, quality control and blinded expert review across our supported cardiac and vascular imaging modalities, supporting consistent endpoint assessment across sites and study timepoints. Specialist cardiac safety services are delivered through a longstanding partnership, with study workflows managed in DYNAMIKA™ and coordinated alongside IAG’s imaging support.

Centralized, secure data collection

DYNAMIKA™ unifies global imaging into a single cloud-native environment — GxP-validated, SOC 2 Type II and 21 CFR Part 11 compliant.

Real-time visibility and oversight

24/7 access to imaging status for every stakeholder, with site and reader performance tracked as the study runs.

Quality control and automated anonymization

Automated checks on receipt produce de-identified, QC-passed datasets before any read begins.

Consistent, standardized reads

Protocol-driven central reviews deliver standardized assessment of cardiac structure, function and vascular imaging measures, using predefined acquisition and analysis methodologies to support consistency across participating sites.
Cardiovascular

Reader management and audit trails

Readers are qualified against the study-specific imaging and assessment methodology, with assignment, blinding and adjudication workflows managed within the platform. Every action is captured in a complete audit trail.
Cardiovascular

Reduced site burden, faster timelines

Simplified upload and query workflows shorten the gap between visit and usable data, and keep central reads inside the data-lock window.
SPEAK TO OUR TEAM

Talk to us about your cardiovascular imaging endpoint

Endpoint selection, charter design, or checking scanner capability at your sites — start with a conversation.

Submit RFP